NCT03186183

GPS: Adaptation Trial of an HIV Prevention Counselling Program for HIV-positive and HIV-negative Gay and Bisexual Men

Completed NA Last updated 10 March 2020

What this trial tests

NA trial testing GPS program in HIV/AIDS in 50 participants. Completed in 17 July 2019.

Timeline

1 September 2017

Primary endpoint
31 March 2019

17 July 2019

Quick facts

Lead sponsor	Toronto Metropolitan University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	50
Start date	1 September 2017
Primary completion	31 March 2019
Estimated completion	17 July 2019
Sites	6 locations across Canada

Drugs / interventions tested

• GPS program

Conditions studied

• HIV/AIDS — all drugs for HIV/AIDS →
• Sexually Transmitted Infection — all drugs for Sexually Transmitted Infection →
• Health Behavior — all drugs for Health Behavior →

Sponsor

Toronto Metropolitan University

Who can join

18 and older, male only, with HIV/AIDS or Sexually Transmitted Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

GPS is a sexual health promotion and HIV prevention peer-delivered counselling program. The GPS program has 4 parts: information provision about HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care. The adaptation grant has three goals: 1) to establish a multi-region and multi-sectoral team that can deliver the revised program across a variety of settings, 2) to learn how best to deliver this program as individual counselling program and also how to adapt this program for HIV-negative MSM, and 3) to pilot the individual program in 5 settings across Ontario and British Columbia. The research team will evaluate the pilot adaptation through mixed methods, employing a quantitative questionnaire and one-on-one semi-structured interviews.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.